301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
The Readout Loud
00:00
Patient-Centric Decision Making in Biotech
The chapter delves into the bold decision by Amalix to withdraw their ALS drug from the market, while ensuring patients with existing prescriptions can continue using it for free. It explores the commendable integrity and patient-focused approach of the co-CEOs, amidst skepticism and hope for a shift towards prioritizing patients over profits in the industry.
Transcript
Play full episode
